Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAESCs transplantation for Parkinson's Disease
NCT05435755Phase 1Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of human amniotic epithelial stem cells in Parkinson's disease (PD) (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: Number of participants with adverse event (AE), serious adverse event(SAE) and adverse events of special interest(AESI) at 12 months. Status: unknown.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05435755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435755.